Abstract
News Beyond Our Pages
Highlights
Hereditary angioedema (HAE) is characterized by recurrent and unpredictable angioedema attacks and occurs as a result of impairment of C1 esterase inhibitor activity, which leads to dysregulation of plasma kallikrein activity and excessive production of bradykinin
All 3 doses of lanadelumab significantly decreased the mean lanadelumab number of HAE attacks per month decreases the frequency of HAE attacks compared with placebo (2.0 attacks per month, P < .001)
The most common adverse effects were injection-site reactions and dizziness. These results demonstrate that prophylactic use of lanadelumab decreases the frequency of HAE attacks
Summary
Hereditary angioedema (HAE) is characterized by recurrent and unpredictable angioedema attacks and occurs as a result of impairment of C1 esterase inhibitor activity, which leads to dysregulation of plasma kallikrein activity and excessive production of bradykinin. Jama.2018.16773) assessed the efficacy of lanadelumab, an mAb that targets active plasma kallikrein, in the prevention of HAE attacks in a multicenter phase 3 trial. Prophylactic randomized to receive one of 3 doses of subcutaneous lanadelumab or placebo use of over 26 weeks. The most common adverse effects were injection-site reactions and dizziness. These results demonstrate that prophylactic use of lanadelumab decreases the frequency of HAE attacks.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
